Skip to main content

Advertisement

Table 4 Proportion of children with 8-fold increase of anti-MSP3 antibodies at day 84 by vaccine type

From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

Antibody 15 μg MSP3 30 μg MSP3 Engerix B
  N n % N n % N n %
Total IgG 15 4 26.7 12 4 33.3 13 1 7.7
IgG1 15 15 100 12 10 83.3 13 2 15.4
IgG2 15 0 0 12 0 0 13 0 0
IgG3 15 13 86.7 12 11 91.7 13 6 46.2
IgG4 15 3 20 12 4 33.3 13 1 7.7
  1. N = total vaccinated, n = responders